Optimizing Antiplatelet Therapy in the ACS Patient: The Intersection of Acute Coronary Syndromes and Oral Antiplatelet Therapy

Faculty

Deepak Bhatt, MD, FACC
Associate Director, Cardiovascular Coordinating Center
Staff, Cardiac, Peripheral and Carotid Intervention
Associate Professor of Medicine
Department of Cardiovascular Medicine
The Cleveland Clinic

Needs Statement

This presentation aims to address the central role of platelets in acute coronary syndromes (ACS) and the use of both oral antiplatelet therapy and interventional therapy as cornerstones for the treatment of ACS. Topics to be discussed include the pharmacology of approved and investigational oral antiplatelet agents, clinical trial data detailing the use of these agents post-ACS, and upcoming investigational trials of current as well as novel therapeutic compounds. The use of non-pharmacologic interventional therapies is also addressed, including the optimal use and management of drug-eluting stents.

Target Audience

This activity is intended for interventional cardiologists, general cardiologists, internists and other healthcare professionals involved in the management of patients experiencing an acute coronary syndrome.

Objectives

1. Describe the pathophysiology of acute coronary syndromes (ACS) as it relates to platelet activation and aggregation and;
2. Identify key oral antiplatlet therapies and their appropriate use in the treatment of ACS.

Accreditation

Medicine
The University of Kentucky College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this educational activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Each physician should claim only those hours of credit actually spent in the educational activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

Faculty Disclosure

Dr. Bhatt serves on the speakers bureau for Bristol-Myers Squibb, Sanofi-Aventis and The Medicines Company; has received research support from The Medicines Company, Bristol-Myers Squibb, Sanofi-Aventis, Eisai, Ethicon and Heartscape; serves as a consultant for Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Centocor, Congentus, Daiichi-Sanyko, Eisai, Eli Lilly and Co., GlaxoSmithKline, Johnson & Johnson, McNeil, Medtronic, Millenium, Molecular Insights, Otsuka, Paringenix, PDL, Philips, Portola, Sanofi-Aventis, Schering-Plough, The Medicines Company, TNS Healthcare and Vertex; and receives honoraia from AstraZeneca, Bristol-Myers Squibb, Eisai, Eli Lilly and Co., GlaxoSmithKline, Millenium, Paringenix, PDL, Sanofi-Aventis, Schering-Plough, The Medicines Company and TNS Healthcare.

Activity Sponsorship